[Translation] Study of the safety, tolerability, pharmacokinetics, immunogenicity, and efficacy of HC006 in patients with advanced solid tumors: a multicenter, open-label, single-agent dose-escalation and multi-cohort expansion Phase I clinical trial
主要目的:评估HC006单药治疗晚期实体瘤患者的耐受性和安全性,确定后续研究推荐剂量。
次要目的:评价HC006单药治疗晚期实体瘤的药代动力学、免疫原性和有效性特征。
[Translation] Main purpose: To evaluate the tolerability and safety of HC006 monotherapy in patients with advanced solid tumors, and to determine the recommended dose for subsequent studies.
Secondary purpose: To evaluate the pharmacokinetics, immunogenicity and efficacy characteristics of HC006 as a single agent in the treatment of advanced solid tumors.